review·Nature Medicine·Apr 1, 2024GREEN OA

Targeting KRAS in cancer

ASAnupriya SinghalCorresponding authorBTBob T. LiEMEileen M. O’Reilly

Memorial Sloan Kettering Cancer Center · Cornell University · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

256
total citations
FWCI
64.17
Percentile
100%
References
138
Citations per year

Authors

3
  • AS
    Anupriya SinghalCorresponding

    Memorial Sloan Kettering Cancer Center

  • BT
    Bob T. Li

    Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine

  • EM
    Eileen M. O’Reilly

    Memorial Sloan Kettering Cancer Center

Topics & keywords

Topics
  • Primary topicPeptidase Inhibition and Analysis100%
  • Chronic Lymphocytic Leukemia Research100%
  • Cancer therapeutics and mechanisms100%
Keywords
  • KRAS
  • Blueprint
  • Computational biology
  • Medicine
  • Cancer research
  • Cancer
  • Bioinformatics
  • Biology
UN Sustainable Development Goals
  • Industry, innovation and infrastructure
No related works found for this paper.

Funding

  • A
    Amgen
  • EL
    Eli Lilly and Company
  • A
    AstraZeneca
  • F
    FibroGen
  • PI
    Parker Institute for Cancer Immunotherapy
  • AP
    Agios Pharmaceuticals
  • E
    Eisai
    Award: P30 CA008748
  • AP
    Astellas Pharma
  • MO
    Ministry of Minority Affairs
  • S
    Servier
  • I
    Ipsen
  • NI
    National Institutes of Health
    Awards: P30 CA008748, NIH P50
  • G
    Genentech
    Award: P30 CA008748
  • NC
    National Cancer Institute
    Awards: K12 CA184746, CA008748, CA257881-01A1, P30 CA008748, P50 CA257881-01A1
  • DS
    Daiichi Sankyo Europe